文献速递妇科生殖医学

不孕症女性生育治疗后卵巢交界性肿瘤的风险:丹麦不孕女性队列研究结果

Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women.
PubMed 文献 · Gynecol Oncol · 2024-02-21

该队列研究基于丹麦不孕症队列,纳入1995年1月1日至2017年12月31日居住于丹麦的20-45岁不孕女性146,891例,通过国家登记库获取生育药物使用及卵巢交界性肿瘤诊断等信息,采用Cox比例风险模型估计风险比(HR)及95%置信区间(CI)。中位随访11.3年期间,144例女性发生卵巢交界性肿瘤;未观察到枸橼酸氯米芬、促性腺激素、促性腺激素释放激素受体调节剂、人绒毛膜促性腺激素或孕酮的曾经使用与卵巢交界性肿瘤(总体及浆液性、黏液性分别分析)存在明显关联,亦未发现按累积剂量、首次使用后时间或产次状态划分的明确关联。

要点

  • 中位随访11.3年,146,891例不孕女性中144例发生卵巢交界性肿瘤。
  • 枸橼酸氯米芬、促性腺激素、促性腺激素释放激素受体调节剂、人绒毛膜促性腺激素或孕酮的曾经使用与卵巢交界性肿瘤无明显关联。
  • 按累积剂量、首次使用后时间或产次状态分析,未发现任何生育药物与卵巢交界性肿瘤的明确关联。

核心结论

  • 未观察到生育药物使用与卵巢交界性肿瘤之间存在明显关联。
  • 队列随访结束时年龄相对较轻,强调对使用过生育药物的女性延长随访期的重要性。

研究设计与样本

  • 该研究为队列研究,基于丹麦不孕症队列,纳入1995年1月1日至2017年12月31日居住于丹麦的20-45岁不孕女性,共146,891例。
  • 通过链接国家登记库获取生育药物使用、卵巢交界性肿瘤及癌症诊断、协变量、移民和生命状态等信息。
  • 采用Cox比例风险模型估计总体卵巢交界性肿瘤及分别针对浆液性和黏液性卵巢交界性肿瘤的风险比(HR)和95%置信区间(CI),并调整潜在混杂因素。

主要发现

  • 中位随访11.3年期间,144例女性发生卵巢交界性肿瘤。
  • 枸橼酸氯米芬、促性腺激素、促性腺激素释放激素受体调节剂、人绒毛膜促性腺激素或孕酮的曾经使用与卵巢交界性肿瘤无明显关联,无论总体分析还是浆液性和黏液性卵巢交界性肿瘤分别分析。
  • 按累积剂量、首次使用后时间或产次状态分析,未发现任何生育药物与卵巢交界性肿瘤的明确关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 队列随访结束时年龄相对较轻,强调对使用过生育药物的女性延长随访期的重要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Results from previous studies examining the association between fertility treatment and borderline ovarian tumors are inconsistent. The aim of this study was to investigate the association between fertility treatment and borderline ovarian tumors in a cohort of infertile women. METHODS: This cohort study was based on the Danish Infertility Cohort and included all infertile women aged 20-45 years living in Denmark between 1 January 1995 and 31 December 2017 (n = 146,891). Information on use of fertility drugs, borderline ovarian tumors and cancer diagnoses, covariates, emigration, and vital status was obtained by linkage to national registers. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) with adjustment for potential confounders for overall borderline ovarian tumors and for serous- and mucinous borderline ovarian tumors separately. RESULTS: During a median 11.3 years of follow-up, 144 women developed a borderline ovarian tumor. No marked associations between ever use of clomiphene citrate, gonadotropins, gonadotropin-releasing hormone receptor modulators, human chorionic gonadotropin or progesterone and borderline ovarian tumors were observed, neither overall nor for serous and mucinous borderline ovarian tumors analysed separately. Further, no clear associations with borderline ovarian tumors were found according to cumulative dose, time since first use or parity status for any fertility drugs. CONCLUSIONS: No marked associations between use of fertility drugs and borderline ovarian tumors were observed. However, the cohort's relatively young age at end of follow-up emphasizes the importance of extending the follow-up period for women who have used fertility drugs.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kristensen AK, Frandsen CLB, Nøhr B, et al. Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women. Gynecol Oncol. 2024. PMID: 38382167. doi:10.1016/j.ygyno.2024.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。